May 11, 2026 4:05 pm EDT Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026
April 2, 2026 5:00 am EDT Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)